Baidu
map

Cancer cell:VEGF能抑制肿瘤细胞浸润和间质上皮转化(MET)

2012-07-16 Beyond 生物谷

血管生成(Angiogenesis)是指从已有的毛细血管或毛细血管后静脉发展而形成新的血管,肿瘤血管生成的发生一方面是由于肿瘤细胞释放血管生成因子激活血管内皮细胞,促进内皮细胞的增殖和迁移,另外一方面也是因为内皮细胞旁分泌某些血管生长因子刺激肿瘤细胞的生长。肿瘤细胞和内皮细胞的相互作用自始至终贯穿于肿瘤血管生成的全过程。 通常,肿瘤新生毛细血管是在原有的血管基础上延伸扩展而形成的,其过程类似于典

血管生成(Angiogenesis)是指从已有的毛细血管或毛细血管后静脉发展而形成新的血管,肿瘤血管生成的发生一方面是由于肿瘤细胞释放血管生成因子激活血管内皮细胞,促进内皮细胞的增殖和迁移,另外一方面也是因为内皮细胞旁分泌某些血管生长因子刺激肿瘤细胞的生长。肿瘤细胞和内皮细胞的相互作用自始至终贯穿于肿瘤血管生成的全过程。

通常,肿瘤新生毛细血管是在原有的血管基础上延伸扩展而形成的,其过程类似于典型的伤口愈合和胚胎形成过程。这些新生血管为不断浸润生长的原发肿瘤提供营养,反过来,肿瘤细胞在生长过程中又分泌多种物质以加速肿瘤新生毛细血管的形成。

越来越多的研究表明,良性肿瘤血管生成稀少,血管生长缓慢;而大多数恶性肿瘤的血管生成密集且生长迅速。因此,血管生成在肿瘤的发展转移过程中起到重要作用,抑制这一过程将能明显阻止肿瘤组织的发展和扩散转移。

但最新研究再次证实用贝伐单抗抑制血管内皮生长因子信号结果导致胶质母细胞瘤(GBM)小鼠模型以及GBM患者体内的肿瘤细胞更具侵袭性。相关研究论文发表在国际权威杂志Cancer cell上。研究数据表明血管内皮生长因子(VEGF)直接负调控肿瘤细胞的侵袭,通过促进蛋白酪氨酸磷酸酶1B(PTP1B)募集到间质上皮转化MET/VEGFR2杂合物中,从而抑制肝细胞生长因子依赖的MET磷酸化和肿瘤细胞迁移。

因此,血管内皮生长因子的封闭抑制反而恢复和增加GBM细胞中MET的活性。因此研究人员认为在阻断血管内皮生长因子时,同时抑制小鼠模型中肿瘤细胞的间质转型和侵袭将会大大提高导患者的生存时间。

doi:10.1016/j.ccr.2012.05.037
PMC:
PMID:

VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex

Kan V. Lu, Jeffrey P. Chang, Christine A. Parachoniak, Melissa M. Pandika, Manish K. Aghi, David Meyronet, Nadezda Isachenko, Shaun D. Fouse, Joanna J. Phillips, David A. Cheresh, Morag Park, Gabriele Bergers

Inhibition of VEGF signaling leads to a proinvasive phenotype in mouse models of glioblastoma multiforme (GBM) and in a subset of GBM patients treated with bevacizumab. Here, we demonstrate that vascular endothelial growth factor (VEGF) directly and negatively regulates tumor cell invasion through enhanced recruitment of the protein tyrosine phosphatase 1B (PTP1B) to a MET/VEGFR2 heterocomplex, thereby suppressing HGF-dependent MET phosphorylation and tumor cell migration. Consequently, VEGF blockade restores and increases MET activity in GBM cells in a hypoxia-independent manner, while inducing a program reminiscent of epithelial-to-mesenchymal transition highlighted by a T-cadherin to N-cadherin switch and enhanced mesenchymal features. Inhibition of MET in GBM mouse models blocks mesenchymal transition and invasion provoked by VEGF ablation, resulting in substantial survival benefit.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1780584, encodeId=68811e805846d, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Jul 28 19:07:00 CST 2012, time=2012-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895632, encodeId=20e11895632cd, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Tue Jan 15 05:07:00 CST 2013, time=2013-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076640, encodeId=b1b720e66402b, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sat Aug 25 12:07:00 CST 2012, time=2012-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868559, encodeId=47b118685593c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Oct 06 04:07:00 CST 2012, time=2012-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958791, encodeId=eb8f1958e91fe, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Aug 16 16:07:00 CST 2012, time=2012-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312870, encodeId=7a1d13128e050, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Wed Jul 18 02:07:00 CST 2012, time=2012-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368460, encodeId=ff5513684600b, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Wed Jul 18 02:07:00 CST 2012, time=2012-07-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1780584, encodeId=68811e805846d, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Jul 28 19:07:00 CST 2012, time=2012-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895632, encodeId=20e11895632cd, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Tue Jan 15 05:07:00 CST 2013, time=2013-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076640, encodeId=b1b720e66402b, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sat Aug 25 12:07:00 CST 2012, time=2012-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868559, encodeId=47b118685593c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Oct 06 04:07:00 CST 2012, time=2012-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958791, encodeId=eb8f1958e91fe, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Aug 16 16:07:00 CST 2012, time=2012-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312870, encodeId=7a1d13128e050, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Wed Jul 18 02:07:00 CST 2012, time=2012-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368460, encodeId=ff5513684600b, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Wed Jul 18 02:07:00 CST 2012, time=2012-07-18, status=1, ipAttribution=)]
    2013-01-15 一闲
  3. [GetPortalCommentsPageByObjectIdResponse(id=1780584, encodeId=68811e805846d, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Jul 28 19:07:00 CST 2012, time=2012-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895632, encodeId=20e11895632cd, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Tue Jan 15 05:07:00 CST 2013, time=2013-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076640, encodeId=b1b720e66402b, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sat Aug 25 12:07:00 CST 2012, time=2012-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868559, encodeId=47b118685593c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Oct 06 04:07:00 CST 2012, time=2012-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958791, encodeId=eb8f1958e91fe, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Aug 16 16:07:00 CST 2012, time=2012-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312870, encodeId=7a1d13128e050, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Wed Jul 18 02:07:00 CST 2012, time=2012-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368460, encodeId=ff5513684600b, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Wed Jul 18 02:07:00 CST 2012, time=2012-07-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1780584, encodeId=68811e805846d, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Jul 28 19:07:00 CST 2012, time=2012-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895632, encodeId=20e11895632cd, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Tue Jan 15 05:07:00 CST 2013, time=2013-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076640, encodeId=b1b720e66402b, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sat Aug 25 12:07:00 CST 2012, time=2012-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868559, encodeId=47b118685593c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Oct 06 04:07:00 CST 2012, time=2012-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958791, encodeId=eb8f1958e91fe, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Aug 16 16:07:00 CST 2012, time=2012-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312870, encodeId=7a1d13128e050, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Wed Jul 18 02:07:00 CST 2012, time=2012-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368460, encodeId=ff5513684600b, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Wed Jul 18 02:07:00 CST 2012, time=2012-07-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1780584, encodeId=68811e805846d, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Jul 28 19:07:00 CST 2012, time=2012-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895632, encodeId=20e11895632cd, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Tue Jan 15 05:07:00 CST 2013, time=2013-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076640, encodeId=b1b720e66402b, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sat Aug 25 12:07:00 CST 2012, time=2012-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868559, encodeId=47b118685593c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Oct 06 04:07:00 CST 2012, time=2012-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958791, encodeId=eb8f1958e91fe, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Aug 16 16:07:00 CST 2012, time=2012-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312870, encodeId=7a1d13128e050, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Wed Jul 18 02:07:00 CST 2012, time=2012-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368460, encodeId=ff5513684600b, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Wed Jul 18 02:07:00 CST 2012, time=2012-07-18, status=1, ipAttribution=)]
    2012-08-16 维他命
  6. [GetPortalCommentsPageByObjectIdResponse(id=1780584, encodeId=68811e805846d, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Jul 28 19:07:00 CST 2012, time=2012-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895632, encodeId=20e11895632cd, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Tue Jan 15 05:07:00 CST 2013, time=2013-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076640, encodeId=b1b720e66402b, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sat Aug 25 12:07:00 CST 2012, time=2012-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868559, encodeId=47b118685593c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Oct 06 04:07:00 CST 2012, time=2012-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958791, encodeId=eb8f1958e91fe, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Aug 16 16:07:00 CST 2012, time=2012-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312870, encodeId=7a1d13128e050, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Wed Jul 18 02:07:00 CST 2012, time=2012-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368460, encodeId=ff5513684600b, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Wed Jul 18 02:07:00 CST 2012, time=2012-07-18, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1780584, encodeId=68811e805846d, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Jul 28 19:07:00 CST 2012, time=2012-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895632, encodeId=20e11895632cd, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Tue Jan 15 05:07:00 CST 2013, time=2013-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076640, encodeId=b1b720e66402b, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sat Aug 25 12:07:00 CST 2012, time=2012-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868559, encodeId=47b118685593c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Oct 06 04:07:00 CST 2012, time=2012-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958791, encodeId=eb8f1958e91fe, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Aug 16 16:07:00 CST 2012, time=2012-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312870, encodeId=7a1d13128e050, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Wed Jul 18 02:07:00 CST 2012, time=2012-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368460, encodeId=ff5513684600b, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Wed Jul 18 02:07:00 CST 2012, time=2012-07-18, status=1, ipAttribution=)]

相关资讯

专家观点:抗VEGF治疗(贝伐单抗)转移性结直肠癌

梅奥诊所 肿瘤学教授 Axel Grothey        1 问:贝伐单抗联合一线化疗治疗转移性结直肠癌(CRC)支持和反对的证据有哪些?        Axel Grothey教授:贝伐单抗起初在3期试验中是添加到目前已过时的IFL方案中(伊立替康,氟尿嘧啶,亚叶酸钙)[1]。IFL治疗目前已不

Cancer Cell:VEGF抑制胶质母细胞瘤间叶上皮组织转化和侵袭性

7月10日,Cancer Cell杂志以精选文章的形式报道了加州大学旧金山分校研究者关于血管内皮生长因子调节多形性胶质母细胞瘤间叶组织转变和侵袭性的最新研究进展。为人们进一步认识肿瘤的抗血管治疗,提供了新线索。 抑制血管内皮生长因子信号,可在多形性胶质母细胞瘤(GBM)的小鼠模型,以及某些贝伐单抗治疗的GBM患者中导致侵袭性增强的表型。 本研究表明,血管内皮生长因子(VEGF)通过加强招募蛋白

Cancer:Angiozyme治疗转移性乳腺癌失败

     RPI.4610 (Angiozyme)是靶向VEGFR-1 mRNA的抗血管生成核糖酶,一项II期研究发现,该药物不能有效治疗转移性乳腺癌病人。该研究1月26日在线发表在《Cancer》上。(Cancer. 2012 Jan 26.)        该研究的45个病人都经过了预处理。93%的病人接受了至少两线的

Oncologist:贝伐单抗联合化疗可能提高疗效

针对肿瘤新生血管形成或血管生成的治疗手段在癌症治疗中占有重要地位,贝伐单抗等针对血管内皮生长因子(VEGF)的单克隆抗体生物制剂在临床上已被广泛运用。 抗血管生成疗法的基本原理是如果肿瘤获得新的血液供应能力有限,那么它们的生长和转移能力也会受到限制。更多的证据表明,修饰和/或“正常化”不规则的肿瘤血管,减少缺氧可加强肿瘤细胞毒性化疗(CT)的功效。 事实上,对于转移性大肠直肠癌,贝伐单抗联合C

Cancer Res.:VEGF在肿瘤中的非促血管生成活性

据6月15日,Cancer Research杂志在线报道,血管内皮生长因子在肿瘤恶性进展过程中所发挥的不仅是促血管生成功能。 血管内皮生长因子/血管通透性因子(VEGF / VPF或VEGF-A)是肿瘤血管生成的关键驱动力,也是治疗恶性肿瘤的重要治疗靶点。然而,很少有研究工作涉及VEGF不依赖于其促血管生成活性的那部分功能。 该研究表明,由肿瘤细胞产生的血管内皮生长因子以自分泌方式,通过与血管

Baidu
map
Baidu
map
Baidu
map